Hoyo: FGFR2/3 inhibitor ABSK061 awarded FDA rare pediatric disease drug qualification.

Hoyu announced that its subsidiary Shanghai Hoyu Biomedical Technology Co., Ltd. has developed a highly selective, orally available small molecule FGFR2/3 inhibitor, ABSK061, which has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of rare pediatric diseases such as achondroplasia.